UCLA Jonsson Comprehensive Cancer Center

Running trials

• Not yet recruiting

  STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection

  NCT07612293· Source

• Not yet recruiting

  Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

  NCT07229339· Phase 2· Source

• Not yet recruiting

  Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

  NCT07468916· Phase 2· Source

• Not yet recruiting

  Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer

  NCT07634601· Phase 2· Source

• Not yet recruiting

  Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients

  NCT07714421· Phase 1· Source

• Not yet recruiting

  Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer

  NCT07716735· Phase 1· Source

• Not yet recruiting

  A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study

  NCT07517211· Source

• Not yet recruiting

  A Disposable Negative Pressure Wound Therapy Device (SNaP) to Promote Wound Healing in the Lower Limbs Following Mohs Micrographic Surgery for Non-melanoma Skin Cancer

  NCT07032701· Source

• Not yet recruiting

  PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma

  NCT06448286· Phase 3· Source

• Recruiting

  Individually Tailored, Supervised, Remote Exercise Intervention to Improve Physical Function for Stage I-III Gastroesophageal Cancer Survivors, PRECISE Trial

  NCT07439484· Source

• Recruiting

  AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

  NCT07619313· Phase 1· Source

• Recruiting

  Intratumoral N17350 in Advanced Solid Tumors

  NCT07339176· Phase 1/2· Source

• Recruiting

  Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer

  NCT07468903· Source

• Recruiting

  Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

  NCT07323641· Phase 2· Source

• Recruiting

  A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

  NCT07280013· Phase 1· Source

• Recruiting

  Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma

  NCT07235280· Early phase 1· Source

• Recruiting

  Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial

  NCT07276438· Source

• Recruiting

  Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial

  NCT07164027· Early phase 1· Source

• Recruiting

  Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients

  NCT07461948· Phase 3· Source

• Recruiting

  Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  NCT06918431· Phase 2· Source

• Recruiting

  An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.

  NCT07185165· Phase 2· Source

• Recruiting

  Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

  NCT04119024· Phase 1· Source

• Recruiting

  Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

  NCT07097142· Phase 3· Source

• Active, not recruiting

  Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

  NCT07118176· Phase 1· Source

• Recruiting

  External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer

  NCT06543576· Phase 1/2· Source

• Recruiting

  ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

  NCT07089641· Phase 1· Source

• Active, not recruiting

  Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of Localized Prostate Cancer, ILLUSION Trial

  NCT06995053· Source

• Recruiting

  A Clinic-wide Intervention (Primary Care-GI Connect) for Improving Rates of Colonoscopy After Abnormal Fecal Immunochemical Test Result in Patients at Federally Qualified Health Centers

  NCT06568016· Source

• Recruiting

  Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer

  NCT06225011· Phase 1· Source

• Recruiting

  Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  NCT06661720· Phase 3· Source

• Recruiting

  Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial

  NCT06432036· Phase 1/2· Source

• Recruiting

  A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  NCT06623422· Phase 3· Source

• Recruiting

  An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer

  NCT06447103· Phase 2· Source

• Recruiting

  Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

  NCT06216249· Phase 2· Source

• Recruiting

  Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

  NCT06288113· Phase 2· Source

• Active, not recruiting

  Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

  NCT06125197· Phase 1· Source

• Recruiting

  Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors

  NCT06113016· Phase 2· Source

• Recruiting

  Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

  NCT05775471· Phase 2· Source

• Recruiting

  Study of Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy for Abdominopelvic Sarcomas (MARS Trial)

  NCT06436612· Phase 2· Source

• Recruiting

  Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy

  NCT05398302· Phase 1· Source

• Recruiting

  Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial

  NCT06067269· Phase 2· Source

• Active, not recruiting

  First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

  NCT06239467· Phase 1· Source

• Recruiting

  An Organoid-based Functional Precision Medicine Trial in Osteosarcoma

  NCT06064682· Source

• Recruiting

  Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

  NCT05987241· Phase 2/3· Source

• Recruiting

  Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps

  NCT06376565· Source

• Recruiting

  Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  NCT05879926· Phase 3· Source

• Recruiting

  Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants

  NCT05978128· Source

• Recruiting

  Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

  NCT05595499· Phase 2· Source

• Recruiting

  Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

  NCT05256641· Phase 1/2· Source

• Active, not recruiting

  Malnutrition Screening and Dietary Intervention to Improve Nutrition Outcomes in Patients With Unresectable Pancreatic Cancer

  NCT06090916· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer13 recruiting
• Childhood cancers10 recruiting
• Lung cancer8 recruiting
• Colorectal cancer6 recruiting
• Kidney cancer5 recruiting
• Glioblastoma4 recruiting
• Melanoma4 recruiting
• Ovarian cancer4 recruiting
• Bladder cancer3 recruiting
• Endometrial cancer3 recruiting
• Head and neck cancer3 recruiting
• Pancreatic cancer3 recruiting
• Sarcoma3 recruiting
• Thyroid cancer3 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Gastric and esophageal cancer2 recruiting
• Liver and biliary tract cancer2 recruiting
• Triple-negative breast cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukemia1 recruiting
• Cervical cancer1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Follicular lymphoma1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting
• Obesity1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)

  NCT05523700· Source

• Terminated

  Focal Laser Ablation of Prostate Cancer: A Feasibility Study Using MRI/US Image Fusion for Guidance

  NCT06047509· Source

• Terminated

  A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL

  NCT05515406· Phase 1· Source

• Completed

  Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study

  NCT04593277· Source

• Terminated

  A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

  NCT05269355· Phase 2/3· Source

• Completed

  Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

  NCT05103358· Phase 2· Source

• Withdrawn

  Cryoablation for the Promotion of Local Tumor Infiltration in Patients With Mesothelioma

  NCT04429204· Source

• Withdrawn

  ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma

  NCT04854044· Phase 1· Source

• Terminated

  Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer

  NCT04473781· Phase 1· Source

• Terminated

  Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

  NCT04205838· Phase 2· Source

• Completed

  Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors

  NCT03953157· Source

• Completed

  Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

  NCT03970252· Early phase 1· Source

• Recruiting

  Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  NCT03866382· Phase 2· Source

• Completed

  Stereotactic Body Radiation Therapy Using HyperArc in Treating Patients With Recurrent Head and Neck Cancer

  NCT03892720· Source

• Completed

  18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

  NCT03732352· Phase 2· Source

• Terminated

  Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

  NCT03107780· Phase 1· Source

• Completed

  Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

  NCT03033576· Phase 2· Source

• Terminated

  A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

  NCT03281369· Phase 1/2· Source

• Completed

  Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02713386· Phase 1/2· Source

• Completed

  Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

  NCT02101905· Phase 1· Source

• Completed

  FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma

  NCT02902757· Source

• Completed

  Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

  NCT02180867· Phase 2/3· Source

• Completed

  Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma

  NCT01849146· Phase 1· Source

• Completed

  Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

  NCT01902173· Phase 1/2· Source

• Completed

  Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

  NCT01771107· Phase 1/2· Source

• Completed

  Scleroderma Treatment With Autologous Transplant (STAT) Study

  NCT01413100· Phase 2· Source

• Completed

  Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

  NCT01231906· Phase 3· Source

• Completed

  Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

  NCT00066690· Phase 3· Source

Trial sites

• University of California Los Angeles - Jonsson Comprehensive Cancer Center,201 S. Buena Vista Street, Suite 2002 trials
• Jonsson Comprehensive Cancer Center2 trials
• UCLA / Jonsson Comprehensive Cancer Center138 trials
• UCLA Jonsson Comprehensive Cancer Center (Site 0135)1 trial
• University of California at Los Angeles / Jonsson Comprehensive Cancer Center1 trial
• University of California Los Angeles - Jonsson Comprehensive Cancer Center1 trial
• University of California, Los Angeles (UCLA) - Jonsson Comprehensive Cancer Center1 trial
• Jonsson Comprehensive Cancer Center1 trial
• UCLA Health, Jonsson Comprehensive Cancer Center1 trial
• UCLA Jonsson Comprehensive Cancer Center2 trials
• University of California Los Angeles - Jonsson Comprehensive Cancer Center2 trials
• University of California Los Angeles - Jonsson Comprehensive Cancer Center,2020 Santa Monica Blvd, Suite 6002 trials
• University of California Los Angeles - Jonsson Comprehensive Cancer Center,2336 Santa Monica, Suites 302 and 3042 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Metastatic breast cancer18 works · 4 trials
• Mesothelioma5 works · 1 trials